FATE News and Press, Fate Therapeutics Inc. From 10/17/21

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion in Assets Under Management. After the Q2-2021 13F filings, the consensus holdings were updated, 6 stocks were removed and 6 added from the u...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q2-2021 13F filings the consensus holdings were updated, 6 stocks were removed and 6 added from the unive...

Gainers: IVAC +7.3%. ERYP +7.3%. FATE +5.3%. CHX +4.8%. XP +3.9%. Losers: CMTL -12.4%. SABR -5.4%. MTCR -2.6%. ZY -2.1%. HAIN -1.9%. For further details see: IVAC, ERYP, CMTL and SABR among after hours movers

SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that one oral and four poster presentations for the C...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q2-2021 13F filings, the consensus holdings were updated. 6 stocks were removed and 6 added from the univ...

Lone Pine Capital’s 13F portfolio value increased from $27.53B to $31.66B. The number of positions decreased from 38 to 36. They added Moderna, RH, and Twitter and increased Square and ServiceNow. Also, they dropped Mercadolibre, Netflix, Atlassian, Bilibili, and Snowflake. ...

Fate fell sharply in August on durability concerns. Its efficacy data, however, was excellent, and safety wasn't too bad either. ASH 2021 in December may help clarify things. For further details see: Fate Therapeutics: We Will Wait For Durability Data

SAN DIEGO, Sept. 15, 2021 (GLOBE NEWSWIRE) --  Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, announced today the publication of preclinical data demonstrat...

Biopharma companies can certainly test even a long-term investor's patience, given that these are the kind of investments that can take quite awhile to bloom. Years of clinical trials, scrutinized results, and a hoped-for (but not guaranteed) approval from the U.S. Food and Drug Administrat...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion in Assets Under Management. After the Q2-2021 13F filings the consensus holdings were updated, 6 stocks were removed and 6 added from the un...